• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    CEO and President Mendelsohn D. Eric covered exercise/tax liability with 394 shares, decreasing direct ownership by 0.41% to 96,133 units (SEC Form 4)

    5/7/25 4:06:59 PM ET
    $NHI
    Real Estate Investment Trusts
    Real Estate
    Get the next $NHI alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Mendelsohn D. Eric

    (Last) (First) (Middle)
    222 ROBERT ROSE DRIVE

    (Street)
    MURFREESBORO TN 37129

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    NATIONAL HEALTH INVESTORS INC [ NHI ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    X Officer (give title below) Other (specify below)
    CEO and President
    3. Date of Earliest Transaction (Month/Day/Year)
    05/05/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 05/05/2025 F 394 D $76.04 96,133(1) D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Options (Right to Buy) 2-25-2021 $69.2 02/25/2021 02/25/2026 Common Stock 41,666 41,666 D
    Stock Options (Right to Buy) 2-25-2021 $69.2 02/25/2022 02/25/2026 Common Stock 41,666 41,666 D
    Stock Options (Right to Buy) 2-25-2021 $69.2 02/25/2023 02/25/2026 Common Stock 41,668 41,668 D
    Stock Option (Right to Buy) 2023 $54.73 02/24/2025 02/24/2028 Common Stock 13,334 13,334 D
    Stock Option (Right to Buy) 2024 $57.76 02/23/2025 02/23/2029 Common Stock 13,333 13,333 D
    Stock Option (Right to Buy) 2024 $57.76 02/23/2026 02/23/2029 Common Stock 13,334 13,334 D
    Stock Option (Right to Buy) 2025 $73.34 03/03/2025 03/03/2030 Common Stock 25,000 25,000 D
    Stock Option (Right to Buy) 2025 $73.34 03/03/2026 03/03/2030 Common Stock 25,000 25,000 D
    Stock Option (Right to Buy) 2025 $73.34 03/03/2027 03/03/2030 Common Stock 25,000 25,000 D
    Explanation of Responses:
    1. Reflects the disposition of 394 restricted shares upon vesting on May 5, 2025 for the settlement of taxes.
    /s/Kimberly V. Ouimet, by limited power of attorney 05/07/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $NHI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NHI

    DatePrice TargetRatingAnalyst
    10/1/2024$81.00 → $86.00Overweight → Equal Weight
    Wells Fargo
    9/24/2024$92.00Buy
    BofA Securities
    3/12/2024$67.00Market Perform → Outperform
    BMO Capital Markets
    2/26/2024$55.00 → $63.00Equal Weight → Overweight
    Wells Fargo
    2/26/2024$57.00 → $64.00Neutral → Outperform
    Wedbush
    1/30/2024$69.00Buy
    Deutsche Bank
    10/3/2023$54.00Neutral
    Wedbush
    9/28/2023$54.00Hold
    Berenberg
    More analyst ratings